UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug

The biotech company is testing a gene therapy called AMT-130 in patients with Huntington's, a genetic brain disorder that causes nerve cells to break down. This leads to a decline in thinking and ability to move.